AP774A - Aqueous risperidone formulations. - Google Patents

Aqueous risperidone formulations. Download PDF

Info

Publication number
AP774A
AP774A APAP/P/1997/000910A AP9700910A AP774A AP 774 A AP774 A AP 774A AP 9700910 A AP9700910 A AP 9700910A AP 774 A AP774 A AP 774A
Authority
AP
ARIPO
Prior art keywords
solution
risperidone
water
solution according
oral
Prior art date
Application number
APAP/P/1997/000910A
Other languages
English (en)
Other versions
AP9700910A0 (en
Inventor
Marc Karel Jozef Francois
Willy Maria Albert Carlo Dries
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP774(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AP9700910A0 publication Critical patent/AP9700910A0/xx
Application granted granted Critical
Publication of AP774A publication Critical patent/AP774A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
APAP/P/1997/000910A 1994-07-11 1995-07-04 Aqueous risperidone formulations. AP774A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/272,462 US5453425A (en) 1994-07-11 1994-07-11 Risperidone oral formulation
US08/429,435 US5616587A (en) 1994-07-11 1995-04-26 Aqueous risperidone formulations
PCT/EP1995/002615 WO1996001652A1 (en) 1994-07-11 1995-07-04 Aqueous risperidone formulations

Publications (2)

Publication Number Publication Date
AP9700910A0 AP9700910A0 (en) 1997-01-31
AP774A true AP774A (en) 1999-10-28

Family

ID=26955530

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/000910A AP774A (en) 1994-07-11 1995-07-04 Aqueous risperidone formulations.

Country Status (37)

Country Link
US (3) US5453425A (et)
EP (1) EP0769965B1 (et)
JP (1) JP2872412B2 (et)
KR (1) KR100212942B1 (et)
CN (1) CN1148226C (et)
AP (1) AP774A (et)
AT (1) ATE206931T1 (et)
AU (1) AU684193B2 (et)
BG (1) BG63070B1 (et)
BR (1) BR9508253A (et)
CA (1) CA2194564C (et)
CY (1) CY2268B1 (et)
CZ (1) CZ285204B6 (et)
DE (1) DE69523313T2 (et)
DK (1) DK0769965T3 (et)
EE (1) EE03426B1 (et)
ES (1) ES2165918T3 (et)
FI (1) FI116510B (et)
HK (1) HK1010691A1 (et)
HR (1) HRP950397B1 (et)
HU (1) HU222352B1 (et)
IL (1) IL114525A (et)
MX (1) MX9700374A (et)
MY (1) MY114389A (et)
NO (1) NO320366B1 (et)
NZ (1) NZ289432A (et)
PH (1) PH31626A (et)
PL (1) PL179972B1 (et)
PT (1) PT769965E (et)
RO (1) RO116778B1 (et)
RU (1) RU2161965C2 (et)
SI (1) SI9500220B (et)
SK (1) SK282159B6 (et)
TR (1) TR199500778A1 (et)
TW (1) TW420615B (et)
WO (1) WO1996001652A1 (et)
ZA (1) ZA955720B (et)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
AU2003250472A1 (en) * 2002-08-23 2004-03-11 Ranbaxy Laboratories Limited Stable aqueous solutions of risperidone and methods for their preparation
WO2004094415A1 (en) * 2003-04-22 2004-11-04 Synthon B.V. Risperidone monohydrochloride
AR044852A1 (es) 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
ES2245891B1 (es) * 2004-07-09 2006-11-16 Clinmet S.L. "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
WO2006129160A2 (en) * 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
ATE424399T1 (de) * 2005-06-29 2009-03-15 Verisfield Uk Ltd Pharmazeutische zusammensetzungen von risperidon in wässriger lösung
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP4922657B2 (ja) * 2006-05-09 2012-04-25 高田製薬株式会社 リスペリドン経口用液剤
WO2007138462A2 (en) * 2006-06-01 2007-12-06 Wockhardt Ltd Aqueous oral formulations of risperidone
CA2687979C (en) * 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
US7776866B2 (en) * 2007-09-15 2010-08-17 Protia, Llc Deuterium-enriched risperidone
ES2868353T3 (es) * 2007-12-19 2021-10-21 Janssen Pharmaceutica Nv Régimen de dosificación asociado a ésteres de paliperidona inyectables de larga acción
ES2731228T3 (es) 2009-01-20 2019-11-14 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Acido benzoico o sales del mismo para mejorar la actividad de un producto farmacéutico
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
CA2850707C (en) * 2011-10-03 2023-03-21 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
US11008277B2 (en) 2016-06-13 2021-05-18 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
CN109563024B (zh) 2016-06-13 2023-06-06 心悦生医股份有限公司 苯甲酸锂的共晶及其用途
BR112019005542A2 (pt) * 2016-09-23 2019-06-18 Delpor Inc composições para compostos de agente terapêutico de pequenas moléculas
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
RU2646812C1 (ru) * 2016-10-24 2018-03-07 Общество с ограниченной ответственностью "Трейдсервис" Жидкая лекарственная форма рисперидона и способ ее получения
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN107260662A (zh) * 2017-06-21 2017-10-20 南京正科医药股份有限公司 一种利培酮口服溶液及其制备方法
CN107441037A (zh) * 2017-08-16 2017-12-08 南京正科医药股份有限公司 一种利培酮口服溶液
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004177A1 (en) * 1987-11-03 1989-05-18 Genentech, Inc. Gamma interferon formulation
WO1992003426A1 (en) * 1990-08-24 1992-03-05 Novo Nordisk A/S Piperazinyl derivatives
WO1994025460A1 (en) * 1993-04-28 1994-11-10 Janssen Pharmaceutica N.V. Risperidone pamoate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337261A (en) * 1980-07-28 1982-06-29 Hoechst-Roussel Pharmaceuticals Inc. (1,2-Benzisoxazol)phenoxyacetic acids as diuretics
FR2641278B1 (fr) * 1989-01-05 1991-03-22 Lipha Piperidines, procedes de preparation et medicaments les contenant
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
FR2796273B1 (fr) * 1999-07-15 2003-09-12 Oreal Composition a phase grasse liquide gelifiee par un polyamide a groupements ester terminaux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004177A1 (en) * 1987-11-03 1989-05-18 Genentech, Inc. Gamma interferon formulation
WO1992003426A1 (en) * 1990-08-24 1992-03-05 Novo Nordisk A/S Piperazinyl derivatives
WO1994025460A1 (en) * 1993-04-28 1994-11-10 Janssen Pharmaceutica N.V. Risperidone pamoate

Also Published As

Publication number Publication date
HRP950397B1 (en) 2002-04-30
US5453425A (en) 1995-09-26
CN1155247A (zh) 1997-07-23
WO1996001652A1 (en) 1996-01-25
CZ285204B6 (cs) 1999-06-16
CA2194564C (en) 1997-12-16
FI970109A0 (fi) 1997-01-10
HK1010691A1 (en) 1999-06-25
NO970051L (no) 1997-01-07
CN1148226C (zh) 2004-05-05
DE69523313D1 (de) 2001-11-22
HRP950397A2 (en) 1997-10-31
HU9700082D0 (en) 1997-02-28
AU2927595A (en) 1996-02-09
JPH09511751A (ja) 1997-11-25
PT769965E (pt) 2002-04-29
KR970704472A (ko) 1997-09-06
TW420615B (en) 2001-02-01
JP2872412B2 (ja) 1999-03-17
ATE206931T1 (de) 2001-11-15
PL179972B1 (pl) 2000-11-30
TR199500778A1 (tr) 1996-10-21
AU684193B2 (en) 1997-12-04
SK2297A3 (en) 1997-09-10
CZ2797A3 (en) 1997-07-16
EE9700009A (et) 1997-08-15
SI9500220A (en) 1996-02-29
ZA955720B (en) 1997-01-10
RU2161965C2 (ru) 2001-01-20
DK0769965T3 (da) 2002-02-04
CY2268B1 (en) 2003-07-04
SI9500220B (sl) 2004-12-31
NO320366B1 (no) 2005-11-28
MY114389A (en) 2002-10-31
HU222352B1 (hu) 2003-06-28
EE03426B1 (et) 2001-06-15
NZ289432A (en) 1998-05-27
DE69523313T2 (de) 2002-06-27
US5616587A (en) 1997-04-01
BG63070B1 (bg) 2001-03-30
CA2194564A1 (en) 1996-01-25
MX9700374A (es) 1997-04-30
FI116510B (fi) 2005-12-15
IL114525A (en) 1999-06-20
RO116778B1 (ro) 2001-06-29
ES2165918T3 (es) 2002-04-01
BG101106A (en) 1997-08-29
EP0769965A1 (en) 1997-05-02
EP0769965B1 (en) 2001-10-17
FI970109A (fi) 1997-01-10
USRE39181E1 (en) 2006-07-11
SK282159B6 (sk) 2001-11-06
PL318132A1 (en) 1997-05-12
AP9700910A0 (en) 1997-01-31
HUT76826A (en) 1997-11-28
NO970051D0 (no) 1997-01-07
PH31626A (en) 1999-01-12
IL114525A0 (en) 1995-11-27
BR9508253A (pt) 1997-12-23
KR100212942B1 (ko) 1999-08-02

Similar Documents

Publication Publication Date Title
AP774A (en) Aqueous risperidone formulations.
US6239141B1 (en) Trovafloxacin oral suspensions
WO2006129160A2 (en) Stable aqueous oral solution of risperidone
IL202961A (en) Oral medical solutions containing Talvivadine
EP1452177A1 (en) Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent
US20060148826A1 (en) Stable aqueous solutions of risperidone and methods for their preparation
US5602148A (en) Liquid compositions based on derivatives of 1,4 substituted piperidine
US5698562A (en) Palatable trimethoprim oral solution
US20030104017A1 (en) Epinastine formulation for oral administration
EP1757294A1 (en) Orally-administered aqueous risperidone solution
KR102242382B1 (ko) 용해성, 안정성 및 쓴맛이 개선된 로라타딘 함유 시럽 조성물
JP4892264B2 (ja) リスペリドン水性液剤
JPWO2004096229A1 (ja) 溶液医薬組成物
EP1739086B1 (en) Pharmaceutical compositions of risperidone in aqueous solution
JP2007302576A (ja) リスペリドン液剤
US5952387A (en) Photostable aqueous solution containing benzyl alcohol derivatives